Clinical trials: Bronchiolitis
Psoriasis, Plaque
A Study to Assess the Severity of Psoriasis in Brazilians Participants With Chronic Plaque-type Psoriasis
The purpose of this study is to assess the severity of plaque-type psoriasis (common genetically determined, chronic, inflammatory skin disease characterized by rounded erythematous, dry, scaling patches.
- Trial name
- NCT02274363
- Testing
- No Intervention
- Where
- 16 sites in Brazil
- Volunteers
- 1,131 people
- Sponsor
- Janssen Pharmaceutica
Chronic Graft Versus Host Disease
Clinical Study to Investigate the Biological Activity, Safety, Tolerability, and Pharmacokinetics of Ponesimod in Subjects With Symptomatic Chronic GVHD
Chronic graft versus host diseasre (GVHD) is a serious reaction that might occur in a person (the host) who has received cells or organs (graft) from another person because the graft attacks the host's cells.
- Trial name
- NCT02461134
- Testing
- Ponesimod
- Volunteers
- 1 people
- Sponsor
- Actelion
Diabetic Foot Ulcers, Venous Ulcers
Registry Trial of the Effectiveness of Platelet Rich Plasma for Chronic Non-Healing Wounds
This study will examine differences in the process of wound-healing in patients treated with platelet rich plasma (a concentration of proteins derived from a patients own blood) applied to the wound as a gel; injected into the…
- Conditions
- Diabetic Foot Ulcers, Venous Ulcers, Pressure Ulcers
- Trial name
- CMS (NCT02071979)
- Testing
- Autologous PRP Gel, Autologous PRP Injections, Autologous PRP Gel plus PRP Injections
- Where
- 6 sites in United States
- Volunteers
- 1,500 people
- Sponsor
- Arteriocyte, Inc.
Cystic Fibrosis Lung, Respiratory Infections, Recurrent, Chronic
A Double-Blind, Active-Controlled, Multiple-Ascending Dose Study of Aerosolized RSP-1502 in Subjects With CF and Chronic PA Lung Infection
A double-blind, active-controlled, multiple-ascending dose, safety study of aerosolized RSP-1502 in subjects with cystic fibrosis Pseudomonas aeruginosa lung infection.
- Conditions
- Cystic Fibrosis Lung, Respiratory Infections, Recurrent, Chronic, Pseudomonas Aeruginosa
- Trial name
- NCT06016088
- Testing
- RSP-1502, Tobramycin inhalation solution
- Where
- 22 sites in United States, Australia
- Volunteers
- 71 people
- Sponsor
- Respirion Pharmaceuticals Pty Ltd
Chronic Graft Versus Host Disease
A Study to Test an Oral Medicine, Belumosudil, in Combination With Corticosteroids in Participants at Least 12 Years of Age With Newly Diagnosed Chronic Graft Versus Host Disease.
This is a parallel, Phase 3, two-arm study for the treatment of newly diagnosed moderate or severe chronic GVHD. The study duration for a participant includes up to 4 weeks for screening; a treatment period until clinically…
- Trial name
- ROCKnrol-1 (NCT06143891)
- Testing
- Belumosudil, Prednisone, Prednisolone
- Where
- 151 sites in United States, Argentina and 22 more
- Volunteers
- 260 people
- Sponsor
- Sanofi
Psoriasis, Plaque Psoriasis
Study to Evaluate Safety and Efficacy of Oral MP1032 in Psoriasis Patients
This Phase IIa study is designed to assess the safety, tolerability and pharmacokinetics of oral MP1032 in patients with moderate to severe psoriasis over a period of 6 weeks.
- Trial name
- NCT02908347
- Testing
- MP1032
- Where
- 4 sites in Germany
- Volunteers
- 46 people
- Sponsor
- MetrioPharm AG
Chronic Graft-versus-Host Disease (cGVHD)
A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of AMG 592 in Healthy Japanese Participants
The primary objective of this study is to characterize the pharmacokinetics (PK) profile of a single dose of AMG 592 administered subcutaneously in healthy Japanese participants.
- Trial name
- NCT05885451
- Testing
- AMG 592
- Where
- Australia
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Amgen
Migraine
An Open Label Extension of a Study of Topiramate in Chronic Migraine.
The purpose of this study is to assess the long-term safety and effectiveness of topiramate for the prevention of headaches in adults with chronic migraine. Topiramate has been approved to prevent migraine headaches.
- Trial name
- NCT00210873
- Testing
- topiramate
- Volunteers
- 200 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Leg Ulcer, Varicose Ulcer
Evaluation of Safety and Activity of Celaderm in Healing Venous Leg Ulcers
This pilot study was designed to test the safety of Celaderm(TM) in treating venous leg ulcers and to give preliminary information about the efficacy of two different Celaderm(TM) dosing regimens.
- Trial name
- NCT00399308
- Testing
- Celaderm (Frozen Cultured Epidermal Allograft), Control (compression bandaging)
- Where
- 9 sites in United States
- Volunteers
- 40 people
- Sponsor
- Shire
URTI, Bronchiolitis
Assessement of Effectiveness of Seawater Nasal Sprays on Sinonasal Symptoms
The purpose of this post-market clinical investigation is to assess in a real-life setting, the effectiveness, usage, tolerance, safety and satisfaction of 4 isotonic and hypertonic seawater-based CE-marked nasal sprays.
- Conditions
- URTI, Bronchiolitis, COVID - 19, Allergic Rhinitis
- Trial name
- SeaBridge (NCT07262450)
- Testing
- Respimer® Hygiene-Prevention -Baby, kids, adults, Respimer® Hygiene-Prevention Kids, adults, Respimer® Decongestion Baby, kids, adults
- Where
- 32 sites in France
- Volunteers
- 1,065 people
- Sponsor
- Laboratoire de la Mer
Graft vs Host Disease
Activity, Safety and Pharmacokinetics in Pediatric Subjects With Moderate and Severe Chronic Graft vs. Host Disease After Allogeneic Stem Cell Transplant
This open-label, single-arm, Phase II multi-center study enrolled 46 participants and investigated the activity, pharmacokinetics and safety of ruxolitinib added to the subject's immunosuppressive regimen among infants, children…
- Trial name
- REACH 5 (NCT03774082)
- Testing
- INC424
- Where
- 21 sites in Brazil, Canada and 12 more
- Volunteers
- 46 people
- Sponsor
- Novartis Pharmaceuticals
Myelodysplastic Syndromes
Safety and Efficacy Study of CC-486 in Subjects With Myelodysplastic Syndromes
Evaluate the safety and efficacy of oral azacitidne (CC-486) twice daily (BID) in subjects with myelodysplastic syndromes who failed to achieve an objective response post injectable hypomethylating agent (iHMA) treatment Reason…
- Trial name
- NCT02281084
- Testing
- Oral Azacitidine, Durvalumab
- Where
- 89 sites in United States, Australia and 8 more
- Volunteers
- 65 people
- Sponsor
- Celgene
Chronic Hepatitis B
Lamivudine Plus Interferon Versus Lamivudine For The Treatment Of HBeAg Positive Chronic Hepatitis B Virus (HBV)
This is a single-centre prospective randomised study comparing the virological and histological response of HBV infection to lamivudine in combination with interferon versus lamivudine alone.
- Trial name
- NCT00140725
- Testing
- Lamivudine plus Polyethylene glyco-interferon alfa-2b, Lamivudine
- Where
- Hong Kong
- Volunteers
- 160 people
- Sponsor
- GlaxoSmithKline
Hepatitis C Virus (HCV)
A Study of of Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus (HCV) Genotype 5 or 6 Infection
A Phase 3b, open-label, multicenter study to evaluate the efficacy and safety of glecaprevir/pibrentasvir for an 8- or 12-week treatment duration in participants with chronic hepatitis C virus (HCV) genotype (GT) 5 or 6…
- Trial name
- ENDURANCE-5 6 (NCT02966795)
- Testing
- Glecaprevir/Pibrentasvir
- Where
- 25 sites in United States, Australia and 7 more
- Volunteers
- 84 people
- Sponsor
- AbbVie
Diabetic Peripheral Neuropathic Pain
Study of the Safety and Efficacy of RGH-896 in Patients With Diabetic Peripheral Neuropathic Pain
This study is designed to evaluate the safety and efficacy of RGH-896 in patients with diabetic peripheral neuropathic pain.
- Trial name
- NCT00838799
- Testing
- RGH-896, pregabalin
- Where
- 54 sites in United States
- Volunteers
- 458 people
- Sponsor
- Forest Laboratories
Migraine
Study of Occipital Nerve Stimulation for Drug Refractory Migraine
The purpose of this study is to evaluate the safety and effectiveness of an implantable device to treat migraine. There are a significant number of patients who have drug refractory migraine and alternative therapies are needed.
- Trial name
- PRISM UK (NCT00747812)
- Testing
- Precision
- Where
- United Kingdom
- Volunteers
- 11 people
- Sponsor
- Boston Scientific Corporation
Chronic Graft-versus-host-disease
Extended Treatment and Follow-up of Subjects Treated With Belumosudil in Study KD025-208 or Study KD025-213
Extended Treatment and Follow-up of Subjects Treated with Belumosudil in Study KD025-208 or Study KD025-213
- Trial name
- NCT05305989
- Testing
- Belumosudil 200 mg QD, Belumosudil 200 mg BID, Belumosudil 400 mg QD
- Where
- 8 sites in United States
- Volunteers
- 23 people
- Sponsor
- Kadmon, a Sanofi Company
Graft vs Host Disease
Theralux Extracorporeal Photochemotherapy (ECP) in Patients With Extensive Chronic Graft Versus Host Disease (GvHD)
The purpose of this study is to assess the tolerability and safety of two intensity levels of Theralux extracorporeal photochemotherapy in the treatment of subjects with steroid refractory or intolerant GvHD.
- Trial name
- NCT00248365
- Testing
- Theralux extracorporeal photochemotherapy
- Where
- 4 sites in Canada
- Volunteers
- 20 people
- Sponsor
- Kiadis Pharma
Diabetic Foot Ulcer
Nitric Oxide Generating Gel Dressing in Patients With Diabetic Foot Ulcers
This is a 2 part study to assess the safety and efficacy of a nitric oxide (NOx) generating dressing on chronic diabetic foot ulcers (DFU). Nitric oxide has a range of effects on the body including vasodilation and angiogenesis.
- Trial name
- ProNOx1 (NCT01982565)
- Testing
- NOx dressing, Standard of Care
- Where
- 10 sites in United Kingdom
- Volunteers
- 130 people
- Sponsor
- Edixomed Ltd
Psoriasis
A Phase 3, Multi Site, Randomized, Double Blind, Placebo Controlled Study Of The Efficacy And Safety Comparing CP- 690,550 And Etanercept In Subjects With Moderate To Severe Chronic Plaque Psoriasis
To evaluate the efficacy of CP-690,550 as compared to etanercept and the safety of CP-690,550 for treatment of moderate to severe chronic plaque psoriasis.
- Trial name
- NCT01241591
- Testing
- CP 690,550 5 mg, CP 690,550 10 mg, Etanercept 50 mg
- Where
- 122 sites in Argentina, Austria and 24 more
- Volunteers
- 1,101 people
- Sponsor
- Pfizer